Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trialJeffrey Clarke, Edward F. Patz, James E. Herndon et al.|Nature Communications|2025Cited by 17
Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).Jeffrey Clarke, Edward F. Patz, Tom Stinchcombe et al.|Journal of Clinical Oncology|2023Cited by 4